

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
6 May 2016 (06.05.2016)



(10) International Publication Number
WO 2016/068802 A1

(51) International Patent Classification:

A61K 39/395 (2006.01) *A61P 35/00* (2006.01)
C07K 16/28 (2006.01) *A61P 37/00* (2006.01)
A61P 31/00 (2006.01)

(21) International Application Number:

PCT/SG2015/050414

(22) International Filing Date:

27 October 2015 (27.10.2015)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

1419094.6 27 October 2014 (27.10.2014) GB

(71) Applicant: **AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH** [SG/SG]; 1 Fusionopolis Way, #20-10 Connexis, Singapore 138632 (SG).

(72) Inventors: **WANG, Cheng-i**; c/o Agency for Science, Technology and Research, 8A Biomedical Grove, #03-00, Singapore 138648 (SG). **OH, Hsueh Ling Janice**; c/o Agency for Science, Technology and Research, 8A Bio-

medical Grove, #03-00, Singapore 138648 (SG). **YEO, Siok Ping**; c/o Agency for Science, Technology and Research, 8A Biomedical Grove, #03-00, Singapore 138648 (SG). **GOH, Yun Pei Sharon**; c/o Agency for Science, Technology and Research, 8A Biomedical Grove, #03-00, Singapore 138648 (SG).

(74) Agent: **SPRUSON & FERGUSON (ASIA) PTE LTD**; P.O. Box 1531, Robinson Road Post Office, Singapore 903031 (SG).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH,

[Continued on next page]

(54) Title: ANTI-TIM-3 ANTIBODIES

1B9 clone

QSVLTQPPSVSAAPGQKVTISCSSSSNIGNNYVSWYQQLPGTAPKLLIYGNN
WRPSGIPDRFSGSKSGTSATLIGITGLQTGDEADYYCEAWDYVYAAGYFGGGT
KLTVL (SEQ ID NO:1)

LC-CDR1: SGSSSNIGNNYVS (SEQ ID NO:10)

LC-CDR2: GNNWRPS (SEQ ID NO:11)

LC-CDR3: EAWDYVYAAGY (SEQ ID NO:12)

1H9 clone

QSVLTQPPSVSAAPGQKVTISCSSSSNIGNNYVSWYQQLPGTAPKLLIYGNN
WRPSGIPDRFSGSKSGTSATLIGITGLQTGDEADYYCDSWDSADASGVFGGGT
KLTVL (SEQ ID NO:2)

LC-CDR1: SGSSSNIGNNYVS (SEQ ID NO:10)

LC-CDR2: GNNWRPS (SEQ ID NO:11)

LC-CDR3: DSWDSADASGV (SEQ ID NO:13)

1H10

QSVLTQPPSVSAAPGQKVTISCSSSSNIGNNYVSWYQQLPGTAPKLLIYGNN
WRPSGIPDRFSGSKSGTSATLIGITGLQTGDEADYYCDSWDYDYAAGVFGGGT
KLTVL (SEQ ID NO:3)

LC-CDR1: SGSSSNIGNNYVS (SEQ ID NO:10)

LC-CDR2: GNNWRPS (SEQ ID NO:11)

LC-CDR3: DSWDYDYAAGV (SEQ ID NO:14)

(57) Abstract: Anti-TIM-3 antibodies are disclosed, as well as pharmaceutical compositions comprising such antibodies, and uses and methods using the same, such as in the treatment of cancer or infectious disease or T-cell dysfunctional disorders. Bispecific antibodies against TIM-3 and other targets are also disclosed, with a preferred embodiment of a bispecific antibody against TIM-3 and CD3.

Figure 1

WO 2016/068802 A1



GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *of inventorship (Rule 4.17(iv))*

Published:

— *with international search report (Art. 21(3))*

— *with sequence listing part of description (Rule 5.2(a))*